Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitogen‑activated protein kinase kinase 7 (MKK7, also known as MAP2K7) is a dual-specificity protein kinase that functions as an essential activator of the c-Jun N-terminal kinases (JNKs) within the mitogen‑activated protein (MAP) kinase signaling cascade. It phosphorylates and activates JNK but not p38 or ERKs. MKK7 plays a central role in transmitting extracellular signals—such as cytokines or environmental stresses—to intracellular effectors that regulate gene expression, apoptosis, inflammation, and cellular differentiation. It is widely expressed across tissues and acts upstream of key cellular decisions involving proliferation versus programmed cell death. Dysregulation of this pathway has been implicated in cancer development/progression and inflammatory diseases[2][7].
Drugs or tool compounds that inhibit MKK7 would block phosphorylation and activation of downstream c-Jun N-terminal kinases (JNKs), thereby modulating cellular responses to stress, inflammation, or apoptosis signals
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitogen-activated protein kinase kinase 7 (MKK7).